In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Stock Party

Executive Summary

Germany has gone equity mad, and biotech stocks are among those enjoying boom times that have seen stock prices sky-rocket in recent months. Some industry observers caution that the party is getting out of hand and that such volatility is dangerous for an industry with long product development cycles. That's why recent moves by MWG-Biotech AG are attracting attention. The firms IPO price was 27 Euros; by mid-February the firm an investment bank helped the company carry out a capital increase, raising over $117 million. MWG's CFO quit suddenly within weeks of the IPO and before the company announced its 1999 numbers. All this may be explainable, but even the perception of impropriety might start a stock slide, according to one analyst.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel